Coronavirus PLpro inhibitor
GRL 0617 is a coronavirus papain-like protease (Plpro) inhibitor (IC50 values are 0.6 and 0.8 μM for SARS-COV and SARS-CoV-2 PLpro, respectively). Inhibits deubiquitination activity of SARS-CoV PLpro. Displays no inhibition of human deubiquitinating enzymes. Improves cell viability following SARS-CoV infection. Inhibits SARS-CoV-2 viral replication and induces antiviral immune signaling pathways following SARS-CoV-2 infection in CaCo-2 cells.
| Marque | Tocris |
|---|---|
| Réf. B-LABO | BL-RE-157965 |
| Réf. fabricant | 18789246 |
| Nom chimique ou matériau | 5-Amino-2-methyl-N-[(1 R)-1-(1-naphthalenyl)ethyl]benzamide |
| CAS | 1093070-16-6 |
| Quantité | 25 mg |
| Cible | Papain-like Protease Inhibitors |
| Formule moléculaire | C<sub>20</sub>H<sub>20</sub>N<sub>2</sub>O |
| Pureté | 0.98 |
